Gabriele Melegari

Dr. Gabriele Melegari

Azienda Ospedaliero Universitaria di Modena
orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2021 in Blood Advances
Verified
Journal Article
Open access
PDF file
Erica VillaErica Villa
Erica Villa
RCrosina maria critelli
rosina maria critelli
SLSimone Lasagni
Simone Lasagni
AMAlessandra Melegari
Alessandra Melegari
ACAngela Curatolo
Angela Curatolo
ADAntonietta Antonia D'Errico
Antonietta Antonia D'Errico
This study examined the association between dynamic angiopoietin-2 assessment and COVID-19 short- and long-term clinical course. We included consecutive hospitalized patients from 1 February to 31 May 2020 with laboratory-confirmed COVID-19 from 2 Italian tertiary referral centers (derivation cohort, n = 187 patients; validation cohort, n = 62 patients). Serum biomarker levels were measured by sandwich enzyme-linked immunosorbent assay. Lung tissue from 9 patients was stained for angiopoietin-2, Tie2, CD68, and CD34. Cox model was used to identify risk factors for mortality and nonresolving pulmonary condition. Area under the receiver operating characteristic curve (AUROC) was used to assess the accuracy of 3- and 10-day angiopoietin-2 for in-hospital mortality and nonresolving pulmonary condition, respectively. Three-day angiopoietin-2 increase of at least twofold from baseline was significantly associated with in-hospital mortality by multivariate analysis (hazard ratio [HR], 6.69; 95% confidence interval [CI], 1.85-24.19; P = .004) with AUROC = 0.845 (95% CI, 0.725-0.940). Ten-day angiopoietin-2 of at least twofold from baseline was instead significantly associated with nonresolving pulmonary condition by multivariate analysis (HR, 5.33; 95% CI, 1.34-11.77; P ≤ .0001) with AUROC = 0.969 (95% CI, 0.919-1.000). Patients with persistent elevation of 10-day angiopoietin-2 levels showed severe reticular interstitial thickening and fibrous changes on follow-up computed tomography scans. Angiopoietin-2 and Tie2 were diffusely colocalized in small-vessel endothelia and alveolar new vessels and macrophages. Angiopoietin-2 course is strongly associated with COVID-19 in-hospital mortality and nonresolving pulmonary condition. Angiopoietin-2 may be an early and useful predictor of COVID-19 clinical course, and it could be a relevant part of disease pathogenesis. Angiopoietin-2 blockade may be a COVID-19 treatment option.

26 July 2022 in Antibiotics
Verified
Journal Article
Open access
PDF file
GBGiulia Jole Burastero
Giulia Jole Burastero
GOGabriella Orlando
Gabriella Orlando
ASAntonella Santoro
Antonella Santoro
MMMarianna Menozzi
Marianna Menozzi
EFErica Franceschini
Erica Franceschini
MMMarianna Meschiari
Marianna Meschiari
Ventilator-associated pneumonia (VAP) in critically ill patients with COVID-19 represents a very huge global threat due to a higher incidence rate compared to non-COVID-19 patients and almost 50% of the 30-day mortality rate. Pseudomonas aeruginosa was the first pathogen involved but uncommon non-fermenter gram-negative organisms such as Burkholderia cepacea and Stenotrophomonas maltophilia have emerged as other potential etiological causes. Against carbapenem-resistant gram-negative microorganisms, Ceftazidime/avibactam (CZA) is considered a first-line option, even more so in case of a ceftolozane/tazobactam resistance or shortage. The aim of this report was to describe our experience with CZA in a case series of COVID-19 patients hospitalized in the ICU with VAP due to difficult-to-treat (DTT) P. aeruginosa, Burkholderia cepacea, and Stenotrophomonas maltophilia and to compare it with data published in the literature. A total of 23 patients were treated from February 2020 to March 2022: 19/23 (82%) VAPs were caused by Pseudomonas spp. (16/19 DTT), 2 by Burkholderia cepacea, and 6 by Stenotrophomonas maltophilia; 12/23 (52.1%) were polymicrobial. Septic shock was diagnosed in 65.2% of the patients and VAP occurred after a median of 29 days from ICU admission. CZA was prescribed as a combination regimen in 86% of the cases, with either fosfomycin or inhaled amikacin or cotrimoxazole. Microbiological eradication was achieved in 52.3% of the cases and the 30-day overall mortality rate was 14/23 (60.8%). Despite the high mortality of critically ill COVID-19 patients, CZA, especially in combination therapy, could represent a valid treatment option for VAP due to DTT non-fermenter gram-negative bacteria, including uncommon pathogens such as Burkholderia cepacea and Stenotrophomonas maltophilia.

29 October 2019 in Journal of Evaluation in Clinical Practice
Verified
Journal Article
Closed access
PDF file
EGEnrico Giuliani
Enrico Giuliani
GMGabriele Melegari
Gabriele Melegari
FCFrancesca Carrieri
Francesca Carrieri
ABAlberto Barbieri
Alberto Barbieri

5 March 2024 in International Journal of Antimicrobial Agents
Verified
Journal Article
Closed access
MMMarianna Meschiari
Marianna Meschiari
MFMatteo Faltoni
Matteo Faltoni
SKShaniko Kaleci
Shaniko Kaleci
GTGiovanni Tassoni
Giovanni Tassoni
GOGabriella Orlando
Gabriella Orlando
CMCristina Mussini
Cristina Mussini

GMGabriele Melegari
Gabriele Melegari
VRVERONICA RIVI
VERONICA RIVI
GZGabriele Zelent
Gabriele Zelent
VNVincenzo Nasillo
Vincenzo Nasillo
ESElena De Santis
Elena De Santis
ABAlberto Barbieri
Alberto Barbieri
The main focus of Coronavirus disease 2019 (COVID-19) infection is pulmonary complications through virus-related neurological manifestations, ranging from mild to severe, such as encephalitis, cerebral thrombosis, neurocognitive (dementia-like) syndrome, and delirium. The hospital screening procedures for quickly recognizing neurological manifestations of COVID-19 are often complicated by other coexisting symptoms and can be obscured by the deep sedation procedures required for critically ill patients. Here, we present two different case-reports of COVID-19 patients, describing neurological complications, diagnostic imaging such as olfactory bulb damage (a mild and unclear underestimated complication) and a severe and sudden thrombotic stroke complicated with hemorrhage with a low-level cytokine storm and respiratory symptom resolution. We discuss the possible mechanisms of virus entrance, together with the causes of COVID-19-related encephalitis, olfactory bulb damage, ischemic stroke, and intracranial hemorrhage.

29 January 2021 in BMJ Evidence-Based Medicine
Verified
Journal Article
Open access
PDF file
VRVERONICA RIVI
VERONICA RIVI
GMGabriele Melegari
Gabriele Melegari
JBJohanna M.C. Blom
Johanna M.C. Blom